長春高新(000661.SZ)：通過兒童藥平台項目入股美國Brillian公司 豐富婦幼用藥領域產品管線
格隆匯7月7日丨長春高新(000661.SZ)宣佈，2020年7月7日，公司第九屆董事會第二十七次會議審議通過了就兒童藥平台項目認購美國特拉華州Brillian Pharma Inc.(下稱“美國Brillian公司”)優先股股權事宜，並授權長春高新經營班子辦理後續《A輪優先股認購協議》等協議的簽署事項。
美國Brillian公司可發行股份數量合計5185.2907萬股，其中2727.6萬股已發行流通。此次投資系由長春高新以2830萬美元認購其增發的2184.9907萬股A輪優先股，佔美國Brillian公司此次增資後股權比例的42.14%。
美國Brillian公司於2020年4月27日在美國特拉華州註冊成立，至今為止有效存續。註冊地址為：251 Little Falls Drive, Wilmington, New Castle, DE 19808, USA。截止至2020年4月30日，美國Brillian公司資產總計5396.66萬元人民幣，2020年1-4月份實現營業收入為35.34萬元人民幣，淨利潤為-19.30萬元人民幣。
兒童用藥是世界性難題，其最大困難在於缺少針對兒童的藥物品種、劑型，以及關於劑量、規格、用法的臨牀數據。由於投入產出不成比例，兒童用藥是醫藥企業不願觸碰的領域。
美國Brillian公司主要進行高端仿製藥與兒童505b2改良藥研發製劑及緩控釋技術高於同行業平均水平。其自主開發的兒童505b2藥物平台針對當下兒童用藥的缺點，開發出具有諸多優勢的液體口服藥物，可以大幅提高兒童患者的依從性。
公司表示，此次投資的目的是豐富長春高新現有產品管線，創造新的利潤空間。此次投資不僅可以藉助其兒童藥平台快速打開國內外市場，還可以提高長春高新現有兒童藥產品的研發能力，豐富婦幼用藥領域產品管線。該項目符合長春高新發展戰略佈局，有利於創造新的利潤空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
